Comparison of the long-term efficacy of silodosin and tamsulodin for the tratment of benign prostatic hyperplasia
Phase 4
- Conditions
- benign prostatic hyperplasia
- Registration Number
- JPRN-UMIN000008538
- Lead Sponsor
- Dokkyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1) with prostatic cancer, prostatitis and urethral stricture, 2) with severe cardiac or cerebrovascular disorders, hepatic disorders, renal dysfunction, 4) on medication with anti-cholinergics, other alpha-AR antagonists, Beta-AR agonists or antagonists, or anti-androgen drugs during 1 month prior to the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate silodosin and tamsulosin in targeting alpha-1 adrenergic receptors for BPH?
How does long-term silodosin efficacy compare to tamsulosin in improving IPSS and QoL metrics for BPH patients?
Which biomarkers correlate with sustained response to silodosin versus tamsulosin in BPH clinical trials?
What are the cardiovascular safety profiles of silodosin and tamsulosin in elderly BPH populations?
How do silodosin and tamsulosin compare to 5-alpha reductase inhibitors in managing BPH-related urinary retention?